About: dbpedia:Zanamivir   Goto Sponge  NotDistinct  Permalink

An Entity of Type : owl:Thing, within Data Space : platform.yourdatastories.eu:8890 associated with source document(s)

Zanamivir INN /zəˈnæmɨvɪər/ is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A and B viruses. It was developed by the Australian biotech firm Biota Holdings. It was licensed to Glaxo in 1990 and approved in the US in 1999, only for use as a treatment for influenza. In 2006, it was approved for prevention of influenza A and B. Zanamivir was the first neuraminidase inhibitor commercially developed.

AttributesValues
rdfs:comment
  • Zanamivir INN /zəˈnæmɨvɪər/ is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A and B viruses. It was developed by the Australian biotech firm Biota Holdings. It was licensed to Glaxo in 1990 and approved in the US in 1999, only for use as a treatment for influenza. In 2006, it was approved for prevention of influenza A and B. Zanamivir was the first neuraminidase inhibitor commercially developed.
foaf:depiction
  • External Image
ATC prefix
  • J05
ATC suffix
  • AH01
Bioavailability
CAS number
  • 139110-80-8
ChEBI
  • 50663
DrugBank
  • DB00558
FDA UNII code
  • L6O3XI777I
IUPAC name
  • (2R,3R,4S)-4-guanidino-3-(prop-1-en-2-ylamino)-2-((1R,2R)-1,2,3-trihydroxypropyl)-3,4-dihydro-2H-pyran-6-carboxylic acid
PubChem
  • 60855
thumbnail
is known for of
Faceted Search & Find service v1.13.91 as of Nov 14 2017


Alternative Linked Data Documents: ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3212 as of Mar 29 2016, on Linux (x86_64-unknown-linux-gnu), Single-Server Edition (68 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2026 OpenLink Software